<DOC>
	<DOC>NCT00503412</DOC>
	<brief_summary>Open, non-randomised, radiolabelled, single centre study with a total of six patients with solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and its metabolites.</brief_summary>
	<brief_title>Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>histologically confirmed metastatic tumor which is refractory to standard therapies life expectancy is 12 weeks or longer WHO performance status is 012 radiotherapy and chemotherapy within 4 weeks before the start of the study treatment patients with a history of poorly controlled hypertension history or evidence of any medical condition that might affect gastrointestinal function patients that have participated in a radiolabelled study in the last 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>phase I</keyword>
	<keyword>AZD2171</keyword>
	<keyword>solid tumor</keyword>
	<keyword>metastatic tumor</keyword>
</DOC>